Published in Nat Rev Cancer on December 01, 2001
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 4.66
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest (2004) 3.70
Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc Natl Acad Sci U S A (2008) 3.29
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol (2010) 2.60
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood (2008) 2.24
The ZO-1-associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density. J Cell Biol (2003) 2.21
Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem (2002) 2.19
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest (2006) 2.18
Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol (2013) 2.17
The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov (2015) 2.15
P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med (2008) 2.10
A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One (2006) 2.05
Initiation of the TORC1-regulated G0 program requires Igo1/2, which license specific mRNAs to evade degradation via the 5'-3' mRNA decay pathway. Mol Cell (2010) 2.01
Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes Dev (2010) 1.88
DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev (2011) 1.82
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst (2012) 1.81
Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther (2007) 1.80
Deregulated G1-cyclin expression induces genomic instability by preventing efficient pre-RC formation. Genes Dev (2002) 1.78
Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci U S A (2009) 1.71
Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev (2004) 1.71
Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell (2007) 1.71
Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J Cell Biol (2009) 1.66
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A (2009) 1.66
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Killing cells by targeting mitosis. Cell Death Differ (2012) 1.65
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest (2007) 1.59
Development of cell-cycle inhibitors for cancer therapy. Curr Oncol (2009) 1.57
Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem (2005) 1.54
Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res (2004) 1.52
Cyclin-dependent kinases. Genome Biol (2014) 1.52
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology (2009) 1.50
Depletion of human histone H1 variants uncovers specific roles in gene expression and cell growth. PLoS Genet (2008) 1.45
Targeting HSP90 for cancer therapy. Br J Cancer (2009) 1.44
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene (2007) 1.44
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A (2006) 1.42
The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene (2006) 1.41
Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol (2004) 1.40
Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol (2004) 1.39
RB1, development, and cancer. Curr Top Dev Biol (2011) 1.37
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Single-cell mass cytometry for analysis of immune system functional states. Curr Opin Immunol (2013) 1.35
Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol (2011) 1.29
Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. Mol Cell Biol (2010) 1.29
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs (2014) 1.26
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
Cyclin A/Cdk2 complexes regulate activation of Cdk1 and Cdc25 phosphatases in human cells. Oncogene (2004) 1.24
A transcriptional program mediating entry into cellular quiescence. PLoS Genet (2007) 1.23
Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol (2007) 1.22
The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol (2002) 1.21
p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes. Mol Cell Biol (2008) 1.19
Studying chromosome instability in the mouse. Biochim Biophys Acta (2008) 1.17
Cdc14b regulates mammalian RNA polymerase II and represses cell cycle transcription. Sci Rep (2011) 1.16
Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15
Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem Biol (2011) 1.15
Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene (2009) 1.15
Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis (2008) 1.11
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med (2014) 1.09
Divisional history and hematopoietic stem cell function during homeostasis. Stem Cell Reports (2014) 1.09
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res (2009) 1.08
CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer (2012) 1.07
The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. J Clin Invest (2010) 1.07
Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J Cancer Res Clin Oncol (2005) 1.05
Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. J Virol (2008) 1.05
Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis. Cancer Res (2007) 1.04
PI3K signaling and miRNA expression during the response of quiescent human fibroblasts to distinct proliferative stimuli. Genome Biol (2006) 1.04
Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci U S A (2013) 1.04
Clinical and technical phosphoproteomic research. Proteome Sci (2011) 1.04
Role of T198 modification in the regulation of p27(Kip1) protein stability and function. PLoS One (2011) 1.04
Stochastic E2F activation and reconciliation of phenomenological cell-cycle models. PLoS Biol (2010) 1.03
Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol (2010) 1.03
Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol (2004) 1.02
Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div (2009) 1.02
Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. Cancer Res (2010) 1.02
The chromatin remodeller CHD8 is required for E2F-dependent transcription activation of S-phase genes. Nucleic Acids Res (2013) 1.01
siRNA-based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model. PLoS One (2010) 1.00
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med (2013) 1.00
The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem (2012) 0.99
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) (2015) 0.99
Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation. PLoS One (2010) 0.98
Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res (2008) 0.97
Cell cycle activation and spinal cord injury. Neurotherapeutics (2011) 0.97
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs (2013) 0.96
Regulation of erythroid differentiation by miR-376a and its targets. Cell Res (2011) 0.95
A Myc-microRNA network promotes exit from quiescence by suppressing the interferon response and cell-cycle arrest genes. Nucleic Acids Res (2013) 0.94
Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells. J Exp Clin Cancer Res (2011) 0.93
Rb and hematopoiesis: stem cells to anemia. Cell Div (2008) 0.93
Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer (2012) 0.93
PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Mol Cell (2014) 0.92
A survivin-ran complex regulates spindle formation in tumor cells. Mol Cell Biol (2008) 0.91
Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine. Neoplasia (2004) 0.90
p27Kip1 and p21Cip1 collaborate in the regulation of transcription by recruiting cyclin-Cdk complexes on the promoters of target genes. Nucleic Acids Res (2015) 0.90
RNA polymerase II transcription is required for human papillomavirus type 16 E7- and hydroxyurea-induced centriole overduplication. Oncogene (2006) 0.90
Promiscuity rules? The dispensability of cyclin E and Cdk2. Sci STKE (2004) 0.90
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol (2016) 0.90
Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly. J Med Chem (2013) 0.89
ras genes. Annu Rev Biochem (1987) 22.59
A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (1982) 11.92
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet (1999) 8.53
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (1986) 5.88
Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol (1994) 5.02
The trk proto-oncogene encodes a receptor for nerve growth factor. Cell (1991) 4.54
T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature (1982) 4.54
Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature (1985) 4.40
Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature (1984) 4.38
Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature (1996) 4.37
gag Gene of mammalian type-C RNA tumour viruses. Nature (1976) 4.11
Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature (1994) 3.73
vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J (1989) 3.67
Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev (1997) 3.45
The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell (1990) 3.21
Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol (1989) 3.10
Oncogenes in solid human tumours. Nature (1982) 3.00
trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell (1991) 2.97
Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature (1992) 2.97
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science (1984) 2.97
Biochemical and immunological characterization of polyproteins coded for by the McDonough, Gardner-Arnstein, and Snyder-Theilen strains of feline sarcoma virus. J Virol (1980) 2.92
Origin and functional properties of the major gene product of the Snyder-Theilen strain of feline sarcoma virus. Proc Natl Acad Sci U S A (1980) 2.83
Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Nature (1994) 2.61
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56
Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc Natl Acad Sci U S A (1982) 2.55
Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell (1993) 2.52
The trichodermin group of antibiotics, inhibitors of peptide bond formation by eukaryotic ribosomes. Biochim Biophys Acta (1973) 2.36
Genetic analysis of ephrin-A2 and ephrin-A5 shows their requirement in multiple aspects of retinocollicular mapping. Neuron (2000) 2.30
Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Curr Biol (1998) 2.26
Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes. Nature (1995) 2.22
Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J (2000) 2.21
K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene (1992) 2.20
Ephrin-A5 (AL-1/RAGS) is essential for proper retinal axon guidance and topographic mapping in the mammalian visual system. Neuron (1998) 2.18
trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO J (1989) 2.14
Topographic guidance labels in a sensory projection to the forebrain. Neuron (1998) 2.03
ras gene Amplification and malignant transformation. Mol Cell Biol (1985) 2.02
Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron (1993) 2.01
Expression of normal and transforming H-ras genes in Escherichia coli and purification of their encoded p21 proteins. Proc Natl Acad Sci U S A (1984) 1.94
Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. Nat Immunol (2001) 1.93
Spontaneous activation of a human proto-oncogene. Proc Natl Acad Sci U S A (1983) 1.90
Nerve growth factor mediates signal transduction through trk homodimer receptors. Neuron (1992) 1.88
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer (2013) 1.85
Expression of the tyrosine kinase receptor gene trkB is confined to the murine embryonic and adult nervous system. Development (1990) 1.75
Tyrosine phosphorylation of the vav proto-oncogene product in activated B cells. Science (1992) 1.73
Mechanism of activation of the vav protooncogene. Cell Growth Differ (1991) 1.71
Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses. J Virol (1979) 1.68
Activation of ras oncogenes preceding the onset of neoplasia. Science (1990) 1.68
Expression of the trk proto-oncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development. Genes Dev (1990) 1.67
Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J (2001) 1.65
Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes. Oncogene (1996) 1.62
Oncogene detection at the single cell level. Oncogene (1988) 1.62
Radioimmunoassay for mammalian type C viral reverse transcriptase. J Virol (1977) 1.58
Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Oncogene (1996) 1.57
Structural polypeptides of mammalian type C RNA viruses. Isolation and immunologic characterization of a low molecular weight polypeptide, p10. J Biol Chem (1976) 1.57
Biological properties and translational products of three independent isolates of feline sarcoma virus. Virology (1979) 1.53
p619, a giant protein related to the chromosome condensation regulator RCC1, stimulates guanine nucleotide exchange on ARF1 and Rab proteins. EMBO J (1996) 1.52
Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. J Biol Chem (1994) 1.49
Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11. Nature (1982) 1.48
The trkB tyrosine protein kinase is a receptor for neurotrophin-4. Neuron (1992) 1.47
Mice lacking brain-derived neurotrophic factor exhibit visceral sensory neuron losses distinct from mice lacking NT4 and display a severe developmental deficit in control of breathing. J Neurosci (1996) 1.46
Evolutionary relationships between gag gene-coded proteins of murine and primate endogenous type C RNA viruses. Cell (1977) 1.45
Membrane properties of the gag gene-coded p15 protein of mouse type-C RNA tumor viruses. J Biol Chem (1978) 1.42
Differential dependency of cutaneous mechanoreceptors on neurotrophins, trk receptors, and P75 LNGFR. Dev Biol (1997) 1.40
Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene (2006) 1.39
TrkB and TrkC signaling are required for maturation and synaptogenesis of hippocampal connections. J Neurosci (1998) 1.36
Synchronous onset of NGF and TrkA survival dependence in developing dorsal root ganglia. J Neurosci (1996) 1.35
Steel factor stimulates the tyrosine phosphorylation of the proto-oncogene product, p95vav, in human hemopoietic cells. J Biol Chem (1992) 1.34
Association of the vav proto-oncogene product with poly(rC)-specific RNA-binding proteins. Mol Cell Biol (1995) 1.33
Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene (1994) 1.30
Isolation and characterization of an endogenous type C RNA virus of mink (Mv1Lu) cells. J Virol (1978) 1.29
TrkA, but not TrkC, receptors are essential for survival of sympathetic neurons in vivo. J Neurosci (1996) 1.29
Differential dependency of unmyelinated and A delta epidermal and upper dermal innervation on neurotrophins, trk receptors, and p75LNGFR. Dev Biol (1998) 1.29
Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene (2010) 1.25
TrkB signaling is required for postnatal survival of CNS neurons and protects hippocampal and motor neurons from axotomy-induced cell death. J Neurosci (1997) 1.25
Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A (2001) 1.24
Molecular analysis of O6-substituted guanine-induced mutagenesis of ras oncogenes. Proc Natl Acad Sci U S A (1989) 1.24
Oncogenes and human cancer: cause or consequence? Carcinogenesis (1986) 1.22
Transforming genes in human tumors. J Cell Biochem (1982) 1.22
Mice with a targeted disruption of the neurotrophin receptor trkB lose their gustatory ganglion cells early but do develop taste buds. Int J Dev Neurosci (1997) 1.22
Dtrk, a Drosophila gene related to the trk family of neurotrophin receptors, encodes a novel class of neural cell adhesion molecule. EMBO J (1992) 1.21
Severe sensory deficits but normal CNS development in newborn mice lacking TrkB and TrkC tyrosine protein kinase receptors. Eur J Neurosci (1997) 1.20
Analysis of translational products of Friend strain of spleen focus-forming virus. J Virol (1978) 1.19
Major structural proteins of type B, type C, and type D oncoviruses share interspecies antigenic determinants. Proc Natl Acad Sci U S A (1980) 1.18
Molecular cloning of the mouse grb2 gene: differential interaction of the Grb2 adaptor protein with epidermal growth factor and nerve growth factor receptors. Mol Cell Biol (1993) 1.15
Frequent generation of oncogenes by in vitro recombination of TRK protooncogene sequences. Proc Natl Acad Sci U S A (1988) 1.15
Identification and biochemical characterization of p70TRK, product of the human TRK oncogene. Proc Natl Acad Sci U S A (1987) 1.14
Origin and biological properties of a new BALB/c mouse sarcoma virus. J Virol (1978) 1.14
Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus. Proc Natl Acad Sci U S A (1980) 1.14
trkC encodes multiple neurotrophin-3 receptors with distinct biological properties and substrate specificities. EMBO J (1993) 1.14
Origin and biological properties of a new feline sarcoma virus. Virology (1982) 1.13
Developmental expression of the vav protooncogene. Cell Growth Differ (1993) 1.13
Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain. Mol Cell Biol (1990) 1.12
A giant protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins forms a cytosolic ternary complex with clathrin and Hsp70. Oncogene (1997) 1.11
The transformation-specific proteins of avian (Fujinami and PRC-II) and feline (Synder--Theilen and Gardner--Arnstein) sarcoma viruses are immunologically related. Virology (1981) 1.11
Wild mouse RNA tumor viruses. A nongenetically transmitted virus group closely related to exogenous leukemia viruses of laboratory mouse strains. J Exp Med (1979) 1.10
Control of spermatogenesis in mice by the cyclin D-dependent kinase inhibitors p18(Ink4c) and p19(Ink4d). Mol Cell Biol (2001) 1.10
Involvement of different exogenous feline leukemia virus subgroups in the generation of independent feline sarcoma virus isolates. Virology (1979) 1.09
Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol Chem (2001) 1.08